Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Interim Report January-September 2017

”Länsförsäkringar Hypotek’s retail mortgage operations are continuing to perform strongly and we see an increase in the number of customers and higher market shares. We delivered a strong operating profit for the period and are further strengthening our market position. The strong local presence of the regional insurance companies and high customer satisfaction are the keys to the stable growth in lending. We are continuing to maintain our high credit quality and loan losses for the period remained unchanged at very low levels. The trend in housing prices remains a much debated issue and it

Interim Report January-September 2017

January-September 2017 compared with January-September 2016: · The Group’s operating profit increased to SEK 2,201 M (1,743), including a positive non-recurring item of SEK 260 M in the first quarter. The return on equity amounted to 11% (10). · Operating profit for the non-life insurance operations increased to SEK 781 M (461), of which SEK 260 M comprised remuneration for the transferred accident and health insurance business to the regional insurance companies. Premiums earned after ceded reinsurance rose to SEK 4,196 M (3,989). The combined ratio amounted to 92% (92). ·

ADDvise signs agreement to acquire AB Germa

•    ADDvise Group AB (publ) has entered into an agreement with Ferno Norden AS and Ferno LLC to acquire all shares in Aktiebolaget Germa with admission planned on December 1st, 2017.•    The purchase price amounts to SEK 17 million. The Acquisition is based on a cash and debt free basis to be paid in cash.•    Germa’s production facility with a market value of SEK 4.5 million is included in the purchase.•    The fiscal year 2016, Germa had a turnover of SEK 30.1 million and generated an EBITDA of SEK 3.4 million. Motives for the acquisition Germa is a profitable product company

Prospectus for Arjo AB (publ) published

Getinge’s wholly-owned subsidiary Arjo AB (publ) has prepared a prospectus regarding the admission to trading of the company’s shares of series B. The prospectus has today been approved and registered by the Swedish Financial Supervisory Authority. Similar to Getinge’s shares of series A, Arjo’s shares of series A will not be listed.The prospectus can be obtained from Getinge and SEB and is available at Getinge’s website, www.getinge.com and at SEB’s website for prospectuses, www.sebgroup.com/prospectuses. For more information: Lars Mattsson, GetingeHead of Investor Relations

Telia Company intends to buy back outstanding bonds

Not for distribution in or into or to any person located or resident in the United States, its territories and possessions (including Puerto Rico, the U.S. Virgin Islands, Guam, American Samoa, Wake Island and the Northern Mariana Islands), any state of the United States or the District of  Columbia or in or into any other jurisdiction where it is unlawful to distribute this announcement.Telia Company AB (the “Issuer”) today announces an invitation to holders of its outstanding EUR 500,000,000 1.375 percent, Notes due February 18, 2019, EUR 750,000,000 4.25 percent, Notes due February 18,

SAS traffic figures - October 2017

• Scheduled traffic (RPK) decreased 3% and the capacity (ASK) was up 2%. • The load factor decreased by 3.8 p.u. versus last year to 74.9%. • Scheduled number of passengers amounted to 2.6 million in October. • The preliminary currency adjusted yield and PASK increased 9% and 4% respectively in October 2017 vs. last year. The nominal yield and PASK increased 7% and 2% respectively in October 2017 vs. last year.Market development and capacity outlook After a robust development of the seasonal demand during the summer, demand has shifted back to more business purpose traveling. In

BerGenBio ASA: Invitation to Third Quarter 2017 Results Presentation and Webcast

Bergen, Norway, 10 November 2017 – BerGenBio ASA, a clinical-stage biopharmaceutical company developing novel, selective Axl kinase inhibitors for multiple cancer indications, will announce its results for the third quarter 2017 on Friday, 17 November 2017.A presentation by BerGenBio’s senior management team will take place at 9.00 am CET at: Thon Hotel Vika Atrium, Munkedamsveien 45, 0250 Oslo Meeting Room: Bjørvika The presentation will webcast live and the link will be available at www.bergenbio.com in the section Investors/Reports and presentations/Webcasts. A recording will be

Selvaag Bolig ASA: Simultaneous interpretation (English) of CMU presentation

A simultaneous interpretation in English of Selvaag Bolig's CMU presentation given in Norwegian 9 November at 09:45 CET is now published at www.selvaagboligasa.no. It can also be found here: http://webtv.hegnar.no/presentation.php?webcastId=72596187 Selvaag Bolig and its affiliates disclaim all liability for any inaccuracies, errors or omissions that may possibly occur in the simultaneous interpretation. Further information fromKristoffer Gregersen, vice president communications and marketing, Selvaag Bolig ASATelephone: +47 957 75 593, e-mail: kgr@selvaagbolig.no Selvaag

IAR Systems adds static and runtime analysis to functional safety tools for Renesas RX MCUs

Latest version integrates powerful code analysis and adds support for Renesas RXv2 coreUppsala, Sweden—November 10, 2017—IAR Systems®, the future-proof supplier of software tools and services for embedded development, launches a new version of the functional safety edition of the complete development toolchain IAR Embedded Workbench® for Renesas RX family of microcontrollers (MCUs). The new version integrates IAR Systems’ add-on tools C-STAT® and C-RUN® for powerful static and runtime analysis. In addition, support for the Renesas RXv2 CPU core is now available. Functional safety is one

Acclaimed international cast confirmed, as Lagardère Studios Distribution signs global distribution of crime thriller Arctic Circle

The series, to be filmed in Finnish Lapland, has completed its cast with new names. Lead roles will feature Iina Kuustonen, Pihla Viitala and acclaimed German actors Maximilian Brückner and Clemens Schick. The Finnish-German co-production will be directed by Hannu Salonen.The Finnish-German co-production will start shooting in a studio in Helsinki at the end of November. The production will continue filming on location in Lapland during winter 2018. The series is co-produced by Yellow Film & TV , the largest independent

ABB appoints Jessica Mitchell as Head of Investor Relations

Zurich, Switzerland, November 10, 2017ABB announced today that Jessica Mitchell has been appointed Head of Investor Relations effective November 15, 2017, reporting to the company’s Chief Financial Officer, Timo J. Ihamuotila. She succeeds Alanna Abrahamson, who has been appointed CFO of ABB’s Industrial Automation division. Abrahamson will assume her new role as of March 1, 2018, after a smooth transition in Investor Relations. Mitchell joins ABB from BP, where she had been Head of Group Investor Relations since August 2011. She has more than 20 years’ experience in the oil and gas

Smart popup packaging for wristwatches wins PIDA Germany 2017

This year’s winner of the BillerudKorsnäs PIDA Germany design competition is a team from Stuttgart Media University. The winning students succeeded in creating a sustainable, smart and attractive packaging solution for wristwatches and other luxury items, called WatchOut.BillerudKorsnäs Packaging Impact Design Award (PIDA), this year celebrates twelve years as an international competition. This year's challenge is based on BillerudKorsnäs own mission, "Challenge conventional packaging for a sustainable future", focused on developing smart and innovative packaging solutions that stands out

Nordstjernan to invest in Lideta Hälsovård

Nordstjernan has reached an agreement with the founding Larsson/Lewné family on acquiring a majority of the shares in Lideta Hälsovård (“Lideta”). Dr. Simon Larsson and Hugo Lewné will remain as shareholders in Lideta, and Mr. Lewné will also remain as CEO. Lideta engages in primary care via 15 units in Stockholm and southern Sweden. The company has grown rapidly since it was founded in 2001 by Dr. Larsson. The company currently has 93,000 listed patients, 350 employees and sales of approximately SEK 500 million. Over the last few years, Lideta has grown through acquisitions and invested

Oskar Röös — New CIO for the Byggmax Group

The Byggmax Group has recruited Oskar Röös as its new CIO and member of Group management.Oskar Röös joins Byggmax from his role as CIO at Espresso House. He has an extensive track record in the development of IT services for the retail, airline and restaurant sectors. “We are delighted to welcome Oskar to Byggmax. His experience as CIO and genuine IT skills together with his values that match well with the Byggmax spirit, make Oskar a welcome addition to Group management,” says Pernilla Walfridsson, CFO of the Byggmax Group. The role of CIO is new and Oskar will report to the Byggmax

Teleste commences co-determination negotiations

TELESTE CORPORATION   PRESS RELEASE   10.11.2017   AT 10:00    TELESTE COMMENCES CO-DETERMINATION NEGOTIATIONS  Teleste is about to commence co-determination negotiations in order to reduce costs, to improve business operations and to secure profitable growth in the coming years.  In order to maintain its leading market position and to achieve its financial targets the company needs to increase operational efficiency and productivity.  Potential personnel reduction need in Finland is estimated to be approx. 30 persons.  Teleste offers an integrated product and service

Höegh LNG : Webcast/Q&A session details for the third quarter of 2017 financial results

Hamilton, Bermuda, 10 November 2017 - Höegh LNG Holdings Ltd. ("Höegh LNG") will release its financial results for the third quarter of 2017 on Thursday 16 November 2017 at 07:00 am CET. In connection with this, Höegh LNG will hold a webcast at 09:00 am CET which will immediately be followed by a Q&A session. The dial-in numbers for the telephone conference are as follows:Norway: +47 2100 2610United Kingdom: +44 (0)330 336 9105United States: +1 323-794-2093 Participant passcode: 2189205The webcast is accessible via a link on Höegh LNG's website or at http://webtv.hegnar.no/

Interim report Scandinavian Enviro Systems AB (publ) January – September 2017

Enviro only qualifier in Chinese government controlled tender processN.B. The English text is an in-house translation of the original Swedish text. Should there be any disparities between the Swedish and the English text, the Swedish text shall prevail. Q3 2017  · Net revenues for the period were MSEK 0.2 (0.0)  · Earnings after tax for the period were MSEK -9.4 (-6.2)   · Earnings per share for the period (before dilution) was SEK -0.08 (-0.13)   · Cash flow for the period after investments was MSEK -6.2 (-2,4)  · New COO Olov Ershag replaces the current Technical

Ripasso Energy signs a letter of intent for sale of seven PWR BLOK units

Ripasso Energy has today signed a letter of intent (LoI) for sale of seven PWR BLOK 400-F units to a South African ferrochrome producer. The potential order value is EUR 3,766,000 with delivery 12 months after a signed order. The LoI has been signed following a successful evaluation of the technical capacity and specifications of the PWR BLOK 400-F by the ferrochrome producer. The parties will now negotiate comprehensive and binding terms for the sale and delivery of the units (the final agreement). Ripasso Energy has granted the ferrochrome producer an exclusive right to purchase

5 years’ follow-up of the first Episealer® patient

Episurf Medical (NASDAQ: EPIS B) announces that the first patient who received an Episealer® knee implant has been on a 5-year follow-up visit. A video from that visit is now available on Episurf Medical's website. Nicolas Martinez Carranza, MD, PhD, performed the very first surgery with the Episealer® knee implant in 2012, after 4 years of pre-clinical research that formed the basis for the development of the implant and associated surgical instruments. In October this year, clinical follow-up and function tests were performed on this first patient.  "I am pleased to note that during

Episurf Medical to present clinical data at Stora Aktiedagen, Stockholm, on November 13

Episurf Medical (NASDAQ: EPIS B) will present clinical data at the event Stora Aktiedagen, Stockholm, on November 13. The presentation will be given by CEO Pål Ryfors and Prof. Leif Ryd, Senior Medical Advisor. The results that will be presented are summarized below. The results show the same trends as previously presented, but are now for larger cohorts. The presently available clinical data for Episealer® patients will be presented. This comprises clinical data for 70 patients that have passed 12 months after Episealer® implantation, as well as data for 30 patients that have passed 24

Balco starts production and delivery of the largest order in the company’s history

Balco is now starting production and delivery of the order for glazed balconies in Östersund which is worth approximately SEK 160 million. The order, which already has been included in the company’s order backlog, is the largest in Balco’s 30-year history and will contribute to revenues towards the end of the fourth quarter of 2017 and throughout 2018.Balco’s customers have now been granted planning permission, and Balco is starting production of balconies to three tenant-owners’ associations in Östersund. The order, which is worth approximately SEK 160 million, is included in the order

Inhalation Sciences assignment in the FORMAMP project on antibiotic resistance is extended by 1,2 MSEK.

Antibiotic resistance is one of the most pressing health concerns on the planet. The EU research project FORMAMP is exploring ways of using Antimicrobial Peptides (AMPs) combined with other nanoformulation strategies, to prevent it. Inhalation Sciences has been contracted to carry out an additional series of studies for the project, extending its role and research revenues.Inhalation Sciences (ISAB) is being contracted to carry out an additional series of studies during 2017 aiming at characterizing silica particles and assess their potential as an inhaled formulation. The extended research

MOBERG PHARMA’S NOMINATION COMMITTEE APPOINTED

STOCKHOLM, November 10th, 2017 - In accordance with the resolution of the Annual General Meeting on May 18, 2017, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee. These shareholders have been invited to appoint one representative each who, together with the Chairman of the Board, will comprise the Nomination Committee. As not all of the company’s three largest shareholders or group of shareholders have wished to appoint such representative, the forth largest shareholder/group of

Interim Report (January - September 2017)

January - September 2017• Net sales amounted to SEK 1,361.5 million (1,266.9), a revenue growth of 7.5 percent. Adjusted for  acquisitions and FX, the organic revenue growth amounted to 1.7 percent.• Operating profit before depreciation and amortization (EBITDA) amounted to SEK 245.7 million  (264.2), corresponding to an EBITDA margin of 18.0 percent (20.8).• Net financial income/expense includes net foreign exchange differences of SEK -23.7 million (19.8).• Profit for the period amounted to SEK 49.3 million (63.9).• Earnings per share after dilution amounted to SEK 0.18 (0.22)

There are no items matching the current filter
There are no more items matching the current filter
Back to top